<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sulfonylurea agent poisoning</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sulfonylurea agent poisoning</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Sulfonylurea agent poisoning</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jason Chu, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Stolbach, MD, MPH, FAACT, FACMT, FACEP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michele M Burns, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert G Hendrickson, MD, FACMT, FAACT</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sulfonylurea agents are commonly used in the treatment of diabetes mellitus. When used appropriately, they promote euglycemia, although hypoglycemia can occur if clearance is impaired or the patient does not eat. Sulfonylureas often cause hypoglycemia with overdose or when ingested by nondiabetic patients.</p><p>The hypoglycemic effects of the sulfonamide antibacterial agents were first discovered in the 1940s. The sulfonylurea medications were first used to treat diabetes mellitus type 2 in 1954, and they remain in widespread use today [<a href="#rid1">1</a>]. Sulfonylureas may be used alone when diet control has failed or in combination with other oral drugs.</p><p>Patients over 65 years, those taking multiple medications, and those who are frequently hospitalized are at increased risk for hypoglycemia [<a href="#rid1">1,2</a>]. Sulfonylurea-related hypoglycemia may also be seen in the setting of unintentional ingestion. Ingestion of a single sulfonylurea pill (ie, 2 mg) by a toddler can cause hypoglycemia [<a href="#rid3">3,4</a>].</p><p>The management of sulfonylurea toxicity will be reviewed here. The therapeutic use of sulfonylureas and other antihyperglycemic agents, the toxicology of other antihyperglycemic agents such as <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, and the general clinical management of drug intoxication are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1786.html" rel="external">"Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/296.html" rel="external">"Metformin poisoning"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PHARMACOLOGY AND TOXICOLOGY</span><span class="headingEndMark"> — </span>Sulfonylurea medications inhibit ATP-sensitive potassium channels in pancreatic beta cell membranes. These potassium channels normally allow for potassium efflux from the cell. Inhibition leads to elevated intracellular potassium concentrations, which results in depolarization. Depolarization causes calcium influx, which activates the secretory system that releases insulin. Sulfonylureas also promote exocytosis of insulin through distinct mechanisms involving direct binding of pancreatic beta cell receptors. In summary, sulfonylurea medications promote hypoglycemia by increasing the release of endogenous insulin [<a href="#rid5">5-7</a>].</p><p>The toxicity of sulfonylurea agents is a direct extension of their normal pharmacology. When used inappropriately (in overdose or in patients without diabetes), hypoglycemia can result.</p><p>Several drug and patient related factors increase the risk of hypoglycemia. Sulfonylurea agents with longer durations of action (eg, <a class="drug drug_general" data-topicid="8494" href="/d/drug information/8494.html" rel="external">glyburide</a>) are more likely to cause such reactions [<a href="#rid1">1,8</a>]. Impaired drug clearance contributes to toxicity in some cases, and renal insufficiency is associated with a fourfold risk of hypoglycemia in patients taking sulfonylureas.</p><p>Drug interactions may also cause hypoglycemia through a number of mechanisms, including decreased hepatic metabolism, increased hypoglycemic activity, and inhibition of membrane transporters  (<a class="graphic graphic_table graphicRef64887" href="/d/graphic/64887.html" rel="external">table 1</a>) [<a href="#rid1">1,9-13</a>]. Certain antibiotics and antifungals are associated with increased risk of hypoglycemia when taken with sulfonylureas [<a href="#rid14">14</a>]. </p><p>Specific interactions of sulfonylureas with other medications may be determined using the <a class="external" href="/drug-interactions">drug interaction program</a> included with UpToDate. This program can be accessed by using the following link (<a class="external" href="/drug-interactions">drug interactions program</a>) or the “Drug Interactions” tab on the UpToDate home page.</p><p class="headingAnchor" id="H3"><span class="h1">KINETICS</span><span class="headingEndMark"> — </span>Sulfonylureas possess a broad range of pharmacokinetic properties  (<a class="graphic graphic_table graphicRef72580" href="/d/graphic/72580.html" rel="external">table 2</a>). In overdose, their onset of action remains unchanged, but their duration of action increases [<a href="#rid15">15</a>]. Peak plasma concentrations are generally achieved within eight hours of an acute ingestion, but may be delayed in overdose. </p><p>Sulfonylureas are metabolized by the liver. Some agents have active metabolites that are renally excreted  (<a class="graphic graphic_table graphicRef51723" href="/d/graphic/51723.html" rel="external">table 3</a>).</p><p>The sulfonylureas are extensively protein bound [<a href="#rid1">1</a>]. The duration of activity, hepatic metabolism, and renal excretion all have implications in the management of patients presenting with sulfonylurea related hypoglycemia.</p><p class="headingAnchor" id="H4"><span class="h1">HISTORY AND PHYSICAL EXAMINATION</span><span class="headingEndMark"> — </span>If possible, clinicians should ask patients about the amount, timing, and reason for any ingestion, what drug was taken, and coingestants including other diabetic medications. Coingestants may mask autonomic symptoms of sulfonylurea overdose. The clinician should attempt to identify any recent illness that may have triggered sulfonylurea-induced hypoglycemia. Age greater than 65 years, taking multiple medications, frequent hospitalization, renal insufficiency, and poor management of diabetes have been associated with sulfonylurea-induced hypoglycemia [<a href="#rid1">1,2,16</a>].</p><p>The remainder of the history and physical examination should focus on identifying the manifestations of hypoglycemia, often divided into neuroglycopenic and autonomic dysfunction. (See  <a class="medical medical_review" href="/d/html/1808.html" rel="external">"Physiologic response to hypoglycemia in healthy individuals and patients with diabetes mellitus"</a>.)</p><p>Neuroglycopenia describes insufficient brain glucose. Common symptoms include confusion, difficulty speaking, dizziness, hemiparesis, seizures, or coma [<a href="#rid17">17</a>]. In short, neuroglycopenia can mimic virtually any neurologic condition.</p><p>Autonomic symptoms are caused by counterregulatory hormones, especially <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>, and include anxiety, nausea, sweating, and palpitations [<a href="#rid18">18,19</a>].</p><p>According to one retrospective chart review of 59 patients, the most common neuroglycopenic symptoms are confusion (83 percent) and personality change (64 percent), while the most common autonomic complaints are diaphoresis (69 percent) and tremulousness (24 percent) [<a href="#rid17">17</a>].</p><p>In infants and young children, the signs of hypoglycemia are frequently nonspecific. They may include irritability, lethargy, abnormal behavior, and with severe hypoglycemia can progress to seizure and coma. Autonomic symptoms are less prominent. With repeated episodes of hypoglycemia, severe manifestations can appear suddenly. (See  <a class="medical medical_review" href="/d/html/5805.html" rel="external">"Approach to hypoglycemia in infants and children"</a>.)</p><p>There is no consistent chronologic order to the evolution of hypoglycemic symptoms.</p><p class="headingAnchor" id="H5"><span class="h1">LABORATORY EVALUATION</span><span class="headingEndMark"> — </span>When hypoglycemia is absent following an unintentional exposure, additional testing is generally unnecessary. Patients with known or suspected sulfonylurea poisoning should have a serum creatinine measured, as a decrease in renal clearance may contribute to toxicity. Serial measurements of serum glucose and baseline measurements of serum electrolytes are appropriate. Further testing is determined clinically. As an example, urine myoglobin and serum creatine kinase are appropriate tests in a patient found on the ground and unresponsive, and thought to be at risk for rhabdomyolysis. </p><p>Routine laboratory evaluation of any poisoned patient, particularly those with a suspected intentional overdose, includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status. This is particularly important in patients who have taken sulfonylurea agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">Acetaminophen</a> and salicylate concentrations, to rule out these common coingestions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiogram, to rule out conduction system poisoning by coingestants that effect the QRS or QTc intervals.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy test, when appropriate.</p><p></p><p class="headingAnchor" id="H430384876"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of sulfonylurea poisoning is made clinically on the basis of a history of overdose or exposure to sulfonylureas and confirmatory clinical and laboratory findings of hypoglycemia, including alterations in mental status (eg, confusion, difficulty speaking, hemiparesis, seizures, coma) and autonomic signs and symptoms (eg, anxiety, sweating, palpations). In the case of pediatric sulfonylurea poisoning, a careful history may reveal a missing tablet belonging to an adult caregiver. In adult poisoning, patients may give a history of intentional overdose. </p><p>In most cases, patients with sulfonylurea poisoning present with undifferentiated hypoglycemia. If available, a medication list may reveal the possibility of sulfonylurea poisoning. Hypoglycemia in the context of a history of sulfonylurea use is sufficient to establish a clinical diagnosis of sulfonylurea poisoning. All suspected cases of sulfonylurea poisoning should be treated empirically. (See <a class="local">'Management'</a> below.)</p><p class="headingAnchor" id="H430384882"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>If the history is unclear, the clinician should consider other causes of hypoglycemia before establishing the diagnosis of sulfonylurea poisoning. However, consideration of the differential diagnosis must not delay the treatment of acute hypoglycemia. The differential diagnosis of low blood glucose is broad and discussed in detail separately; alternative diagnoses of particular relevance to the patient with sulfonylurea poisoning are discussed briefly below. (See  <a class="medical medical_review" href="/d/html/1798.html" rel="external">"Hypoglycemia in adults without diabetes mellitus: Determining the etiology"</a> and  <a class="medical medical_review" href="/d/html/5805.html" rel="external">"Approach to hypoglycemia in infants and children"</a>.). </p><p>A number of diseases  (<a class="graphic graphic_table graphicRef78919" href="/d/graphic/78919.html" rel="external">table 4</a>) and medications  (<a class="graphic graphic_table graphicRef52892" href="/d/graphic/52892.html" rel="external">table 5</a>) can cause hypoglycemia. Diseases that increase insulin secretion (eg, insulinomas) or decrease insulin availability (eg, insulin antibodies or insulin receptor antibodies) can cause hypoglycemia. Antibodies can cause hypoglycemia when they function as insulin receptor agonists or, rarely, when they bind insulin and prolong its duration of activity [<a href="#rid20">20</a>]. In addition, deficiencies in cortisol or <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a>, as well as severe illness from sepsis, hepatic failure, or malnutrition may cause hypoglycemia. However, patients with severe, acute presentations of such deficiencies or diseases are generally ill appearing and manifest signs and symptoms of those conditions in addition to signs and symptoms (such as confusion and autonomic findings) attributable to sulfonylurea poisoning. Prominent features of adrenal crisis include fever and abdominal pain; septic patients are often febrile with abnormal vital signs and a source of infection; hepatic failure may manifest with abdominal complaints (pain, vomiting, distension), characteristic laboratory abnormalities (elevated PT and Bilirubin), jaundice, and encephalopathy. </p><p>Drugs such as insulin, meglitinides, or alcohol may cause hypoglycemia. Rarely, insulin is surreptitiously administered with the intent to harm. If a patient is taking insulin and a sulfonylurea, it may be impossible to determine the degree to which each drug contributed. </p><p>Laboratory results can be used to support the diagnosis but should not delay treatment. Because sulfonylureas cause release of endogenous insulin, proinsulin and c-peptide concentrations will be elevated along with insulin concentrations. Very rarely, individuals ingest illegally obtained sulfonylureas because the tablets have a similar appearance to misused substances such as <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a> or <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a>. Confirmatory sulfonylurea assays may be available in many institutions, but usually require several days for results and thus, play no role in acute clinical management. </p><p class="headingAnchor" id="H6"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H7"><span class="h2">Hypoglycemia</span><span class="headingEndMark"> — </span>When hypoglycemia is recognized, <a class="drug drug_general" data-topicid="8711" href="/d/drug information/8711.html" rel="external">intravenous dextrose</a> (D-glucose) is administered (0.5 to 1 g/kg IV) to increase blood glucose acutely. Symptomatic hypoglycemia from intentional sulfonylurea overdose is treated with both dextrose and <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a>; the role of octreotide in hypoglycemia associated with therapeutic use of sulfonylureas is unclear. (See <a class="local">'Symptomatic intentional overdose'</a> below and <a class="local">'Unintentional single-episode hypoglycemia'</a> below.)</p><p>In adults, the initial treatment is generally 25 g (50 mL) of 50 percent dextrose (D50W) solution. In infants and children, a weight-based bolus of dextrose (0.5 to 1 g/kg) is given IV. Children are treated with a 25 percent (D25W) or 10 percent (D10W) dextrose solution, and neonates with a 10 percent dextrose solution. Doses of dextrose may be repeated.</p><p>Basic pediatric dosing is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>D10W: Give 5 to 10 mL/kg</p><p class="bulletIndent1"><span class="glyph">●</span>D25W: Give 2 to 4 mL/kg</p><p class="bulletIndent1"><span class="glyph">●</span>D50W: Give 1 to 2 mL/kg</p><p></p><p>If <a class="drug drug_general" data-topicid="9988" href="/d/drug information/9988.html" rel="external">thiamine</a> deficiency (from alcoholism or other forms of malnutrition) is suspected, parenteral thiamine (100 mg IV) is given in conjunction with glucose. (See  <a class="medical medical_review" href="/d/html/4818.html" rel="external">"Wernicke encephalopathy"</a>.)</p><p><a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">Glucagon</a> (5 mg) given intramuscularly (IM) raises serum glucose slightly and may be used as a temporizing measure while IV access is obtained, but it is not a substitute for dextrose [<a href="#rid21">21</a>]. The efficacy of glucagon is dependent upon hepatic glycogen stores, which may be depleted in the setting of prolonged hypoglycemia [<a href="#rid15">15</a>]. The short duration of action of glucagon further limits its effectiveness.</p><p>Once clinical euglycemia is established based on clinical findings, and generally accompanied by a serum glucose ≥60 mg/dL (3.3 mmol/L), the patient should be fed a calorie-rich meal. Fifty mL of 50 percent dextrose in sterile water (D50W) contains only 25 g of dextrose or 100 calories, whereas food provides a calorie-rich and longer lasting source of glucose.</p><p>Further treatment and disposition vary depending on the class of agent causing the toxicity and the severity of symptoms.</p><p class="headingAnchor" id="H8"><span class="h2">Intoxication</span><span class="headingEndMark"> — </span>The clinician is most likely to encounter one of three possible intoxication scenarios: a patient with a sulfonylurea overdose and symptomatic hypoglycemia; a patient who develops a hypoglycemic episode with therapeutic use of a sulfonylurea agent; and the asymptomatic (usually pediatric) patient with an acute exposure and a normal serum glucose.</p><p class="headingAnchor" id="H9"><span class="h3">Symptomatic intentional overdose</span><span class="headingEndMark"> — </span>The patient with a sulfonylurea overdose and symptomatic hypoglycemia should be treated with both <a class="drug drug_general" data-topicid="8711" href="/d/drug information/8711.html" rel="external">intravenous dextrose</a> and <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a>. Intravenous dextrose is administered, as described above, to raise the blood glucose acutely, thereby increasing glucose delivery to the brain (see <a class="local">'Hypoglycemia'</a> above). Octreotide is a somatostatin analog that inhibits insulin release from pancreatic beta-islet cells. </p><p><a class="drug drug_general" data-topicid="8711" href="/d/drug information/8711.html" rel="external">Intravenous dextrose</a>, while crucial for resuscitation, should not be used as monotherapy for a sulfonylurea overdose. When given alone, IV dextrose may cause a transient hyperglycemia that triggers increased insulin release, leading to recurrent episodes of hypoglycemia. This increase in insulin release can be minimized by <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a>. Octreotide dosing is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In adults, the dose of <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> is 50 to 100 mcg administered by intramuscular, or subcutaneous, injection every six hours. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In children, the dose of <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> is 1 to 1.5 mcg/kg (up to 50 mcg) every six hours. </p><p></p><p><a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">Octreotide</a> may also be given as an IV bolus over several minutes or by continuous IV infusion [<a href="#rid22">22</a>]. In almost all cases, intermittent intramuscular and subcutaneous dosing is sufficient and IV infusion is unnecessary to maintain normoglycemia. </p><p>Serum glucose should be periodically monitored to identify any recurrence of hypoglycemia. The optimal interval is not known. Once the initial hypoglycemia is corrected, we suggest measuring blood glucose twice more at 30 minute intervals. If the patient maintains euglycemia, serum glucose can be checked every four to six hours thereafter.</p><p>In our experience, this approach is usually sufficient to prevent further hypoglycemia and no additional dextrose is needed. If desired, a dextrose infusion may be provided as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Pediatric dextrose infusion: 6 to 9 mg/kg per minute. The rate of glucose infusion can be calculated as follows:</p><p></p><p class="bulletIndent1">Rate of infusion (mg/kg per minute) = (Percent dextrose in solution x 10 x rate of infusion [mL per hour]) ÷ (60 x weight [kg])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adult dextrose infusion: 75 to 100 mL/hour of a 5 percent dextrose solution (D5W)</p><p></p><p><a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">Octreotide</a> should be administered for 24 hours. After octreotide is discontinued, the patient is monitored for hypoglycemia for another 24 hours to ensure there is no remaining drug or active metabolite. If hypoglycemia recurs during this period, we suggest restarting octreotide therapy for another 24 hours. In addition, two serum glucose measurements should be obtained 30 minutes apart during the first hour, and every four to six hours thereafter, provided euglycemia is maintained.</p><p>A small number of controlled trials and multiple case reports describe successful treatment of sulfonylurea-related hypoglycemia with <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> in adult diabetic and nondiabetic patients [<a href="#rid1">1,23-27</a>]. A retrospective review of nine adult patients treated for sulfonylurea-related hypoglycemia showed that 2.9 ampules of D50W were needed for each patient before octreotide treatment but only 0.2 ampules thereafter [<a href="#rid23">23</a>]. The risk for hypoglycemia before octreotide treatment was 27 times the risk of hypoglycemia after treatment. A small, limited randomized trial found that patients treated with a single dose of octreotide in addition to standard care maintained higher serum glucose over eight hours and sustained fewer episodes of hypoglycemia than patients treated with standard care alone [<a href="#rid28">28</a>].</p><p>Children also benefit from <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> therapy. A review of 121 pediatric cases involving children less than six years reported that treatment with octreotide substantially reduced hypoglycemic episodes (median of 2 [range 0-9] hypoglycemic events before octreotide versus median of 0 [range 0-5] after octreotide) and caused no adverse effects. Most patients (82 percent) did not develop hypoglycemia after treatment, but 18 percent experienced hypoglycemia after the first dose (median five hours later) [<a href="#rid29">29</a>].</p><p>Several mechanisms of action have been proposed for <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a>, but the most important is thought to be a G-protein-mediated decrease in calcium influx through voltage-gated channels in pancreatic beta islet cells. Decreased calcium influx diminishes calcium-mediated insulin release [<a href="#rid30">30</a>]. The drug is rapidly and completely absorbed when given subcutaneously, reaching 100 percent bioavailability within 30 minutes [<a href="#rid31">31</a>].</p><p><a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">Octreotide</a> has replaced <a class="drug drug_general" data-topicid="9346" href="/d/drug information/9346.html" rel="external">diazoxide</a> as a treatment for sulfonylurea-induced hypoglycemia [<a href="#rid15">15,32</a>]. Diazoxide hyperpolarizes the islet cell membrane, inhibiting calcium influx, and thus, the calcium-dependent release of insulin. A study comparing dextrose, diazoxide, and octreotide in normal volunteers showed that octreotide produces a significantly greater decrease in insulin secretion and glucose requirements [<a href="#rid32">32</a>]. Diazoxide can also cause hypotension.</p><p>In the presence of an acute overdose (ie, within two hours), activated charcoal (AC) may be given to prevent absorption of the sulfonylurea. Charcoal should be withheld in patients who are sedated and may not be able to protect their airway, unless endotracheal intubation is performed first. Endotracheal intubation should not be performed solely for the purpose of giving charcoal. (See  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient"</a>.)</p><p>Serum electrolytes should also be obtained. Chlorpropamide has been associated with dose-independent symptomatic hyponatremia related to inappropriate secretion of antidiuretic hormone [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/d/html/2384.html" rel="external">"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)", section on 'Drugs'</a>.)</p><p>There are limited data on hemodialysis for sulfonylurea ingestions. The drugs exhibit high protein binding which theoretically makes hemodialysis ineffective. There are a few case reports of hemoperfusion being used successfully in a sulfonylurea overdose [<a href="#rid34">34,35</a>].</p><p class="headingAnchor" id="H10"><span class="h3">Unintentional single-episode hypoglycemia</span><span class="headingEndMark"> — </span>Management of the patient with a single episode of hypoglycemia during therapeutic sulfonylurea use (not overdose) is less straightforward. <a class="drug drug_general" data-topicid="8711" href="/d/drug information/8711.html" rel="external">Intravenous dextrose</a> is appropriate to correct symptomatic hypoglycemia, but the role for <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> is less clear. We recommend feeding such patients a calorie-rich meal, holding their sulfonylurea medication, and observing them in the hospital for 24 hours. Because we recommend up to 24 hours of additional glucose monitoring following the last administration of octreotide, we do not suggest octreotide therapy for a single episode of hypoglycemia under these circumstances.</p><p>If the patient remains euglycemic during the 24 hour observation period, we believe that the patient may be safely discharged. If the patient develops a second episode of hypoglycemia, we recommend that <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> be administered in the same manner and monitoring schedule as described above for patients with an overdose. (See <a class="local">'Hypoglycemia'</a> above.)</p><p>The management of patients who present to their primary care physicians (PCP) with mild symptoms of hypoglycemia during therapeutic sulfonylurea use may differ from that of patients who present to the emergency department. PCPs who know the patient well may elect to discharge the patient home after a thorough evaluation and a period of observation, provided the following criteria are met:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms are mild and resolve rapidly and completely following simple treatment (eg, juice and a meal), and do not recur over a few hours of observation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is a clear history of inadequate food intake preceding the development of symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum glucose is maintained above 80 mg/dL (4.4 mmol/L) over a few hours of observation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History, physical examination, and possibly laboratory studies (eg, BUN and creatinine) do not raise concerns about comorbid disease or impaired drug clearance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Responsible caretakers will remain with the patient for the next 24 hours to ensure that finger stick blood sugars are monitored closely (eg, every four hours), remain over 80 mg/dL (4.4 mmol/L), and that symptoms do not recur.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Appropriate follow-up is arranged.</p><p></p><p>Observation in the hospital is indicated if the patient does not meet all these criteria, or if the clinician has concerns about the patient's condition or whether appropriate monitoring can be performed at home.</p><p class="headingAnchor" id="H11"><span class="h3">Pediatric considerations</span><span class="headingEndMark"> — </span>The management of an asymptomatic, euglycemic child presenting with a history of a sulfonylurea exposure is challenging. Ingestions of a single sulfonylurea pill as small as 2 mg can cause hypoglycemia in young children. Activated charcoal should be given if it is within two hours of the ingestion and the patient will tolerate it. Activated charcoal is unlikely to be effective in symptomatic children since hypoglycemia from sulfonylurea often occurs hours after the ingestion.</p><p>In an asymptomatic child with a sulfonylurea exposure, we recommend in-hospital observation for 12 to 24 hours. If a 12-hour observation would lead to discharge at night, patients should be observed until the morning. Hypoglycemia (if present) will typically occur within eight hours although delayed hypoglycemia has occurred [<a href="#rid3">3,4,36-39</a>]. If the patient becomes hypoglycemic, standard treatment is provided. (See <a class="local">'Hypoglycemia'</a> above.)</p><p>Some experts will monitor a young child (≤5 years) at home if they ingested no more than one pill of a second-generation sulfonylurea (eg, <a class="drug drug_general" data-topicid="8494" href="/d/drug information/8494.html" rel="external">glyburide</a>, <a class="drug drug_general" data-topicid="8785" href="/d/drug information/8785.html" rel="external">gliclazide</a>, <a class="drug drug_general" data-topicid="8492" href="/d/drug information/8492.html" rel="external">glipizide</a>, <a class="drug drug_general" data-topicid="8491" href="/d/drug information/8491.html" rel="external">glimepiride</a>), can be closely and reliably monitored, and remain asymptomatic. Home monitoring is not appropriate after an ingestion of an extended-release formulation, a first-generation sulfonylurea, &gt;4 mg glimepiride, or an evening or nighttime ingestion. Home monitoring recommendations typically include eating a complex carbohydrate-rich, age-appropriate meal and staying awake for six hours. This approach was initially designed and may be most appropriate for rural settings where transport to an acute-care facility solely for monitoring is logistically infeasible. If the patient is close to or already in an acute-care facility (eg, emergency department), most experts would not recommend nighttime home monitoring. A retrospective poison center study of 115 children (≤5 years) who ingested ≤1 pill of a second-generation sulfonylurea and were initially managed at home found that 4 percent (five patients) developed asymptomatic hypoglycemia after referral to a health care facility, two patients received <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> at the discretion of the treating physician, and none developed seizure or coma [<a href="#rid40">40</a>].</p><p>The dose of sulfonylurea necessary to cause hypoglycemia in small children is difficult to determine based on available evidence, and will depend on a range of factors, such as when the child last ate, whether the child is ill or malnourished, and the size of the child. It is best to err on the side of caution and observe the child in the hospital if any doubt exists about the nature of the ingestion.</p><p class="headingAnchor" id="H12"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H3991650149"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H1895930607"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacology</strong> – Sulfonylurea agents are commonly used to treat of diabetes mellitus by increasing insulin release but can also cause hypoglycemia. Risk factors for hypoglycemia from therapeutic use include (see <a class="local">'Pharmacology and toxicology'</a> above and <a class="local">'Kinetics'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age over 65 years</p><p class="bulletIndent2"><span class="glyph">•</span>Taking multiple medications</p><p class="bulletIndent2"><span class="glyph">•</span>Frequent hospitalization</p><p class="bulletIndent2"><span class="glyph">•</span>Use of agents with longer durations of action (eg, <a class="drug drug_general" data-topicid="8494" href="/d/drug information/8494.html" rel="external">glyburide</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Impaired drug clearance (eg, renal or hepatic dysfunction)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>History and physical examination</strong> – Inquire about the amount, timing, and reason for any ingestion, what drug was taken, and co-ingestants, including other diabetic medications. Hypoglycemia generally manifests with neurologic and autonomic symptoms. Among the most common are confusion, personality change, diaphoresis, and tremulousness, but symptoms can be masked by co-ingestants. (See <a class="local">'History and physical examination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory evaluation</strong> – In a patient with an intentional overdose or at risk for poisoning from other agents, obtain the following studies: fingerstick glucose, serum electrolytes, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> and salicylate concentrations, serum creatinine, electrocardiogram, and a pregnancy test, when appropriate. (See <a class="local">'Laboratory evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypoglycemia</strong> – When hypoglycemia is recognized, administer intravenous (IV) dextrose (0.5 to 1 g/kg IV) to increase blood glucose acutely. In adults, the initial bolus is generally given as 25 g (50 mL) of a 50% dextrose (D50W) solution. In children, a 25% dextrose solution is used, while in infants and neonates, a 10% dextrose solution is used. (See <a class="local">'Hypoglycemia'</a> above.)</p><p></p><p class="bulletIndent2">After treatment, obtain serial measurements of fingerstick glucose twice more at 30-minute intervals, and if the patient maintains euglycemia, serum glucose can be checked every four to six hours thereafter.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intentional overdose</strong> – In a patient with a sulfonylurea overdose and symptomatic hypoglycemia, we suggest immediate treatment with <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>) in addition to <a class="drug drug_general" data-topicid="8711" href="/d/drug information/8711.html" rel="external">IV dextrose</a> instead of IV dextrose alone. In adults, the dose of octreotide is 50 to 100 mcg administered by intramuscular or subcutaneous injection every six hours; in children the dose is 1 to 1.5 mcg/kg (up to 50 mcg) every six hours. (See <a class="local">'Symptomatic intentional overdose'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypoglycemia during therapeutic dosing</strong> – In a patient with a single episode of hypoglycemia during therapeutic sulfonylurea use (not overdose), treatment consists of <a class="drug drug_general" data-topicid="8711" href="/d/drug information/8711.html" rel="external">IV dextrose</a> followed by a calorie-rich meal, discontinuation of sulfonylurea medications, and 24 hours of in-hospital observation with close monitoring of the serum glucose. If the patient develops a second episode of hypoglycemia, we suggest treating with <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> in the same manner as described above for a patient with an overdose. (See <a class="local">'Unintentional single-episode hypoglycemia'</a> above.)</p><p></p><p class="bulletIndent2">Primary care physicians may elect to discharge home patients they know well who present to the clinic with mild symptoms of hypoglycemia during therapeutic sulfonylurea use, provided symptoms are mild and resolve, there is a clear history of inadequate food intake prior to hypoglycemia, serum glucose is maintained above 80 mg/dL, there is a responsible caretaker, and follow-up is arranged. (See <a class="local">'Unintentional single-episode hypoglycemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pediatric consideration</strong> – In an asymptomatic child with a sulfonylurea exposure, we recommend in-hospital observation for 12 to 24 hours. If a 12-hour observation would lead to discharge at night, patients should be observed until the morning. Delayed hypoglycemia has occurred following ingestion of a number of medications, and a single sulfonylurea pill as small as 2 mg can cause hypoglycemia in a young child. If the patient becomes hypoglycemic, standard treatment is provided. (See <a class="local">'Pediatric considerations'</a> above and <a class="local">'Hypoglycemia'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994; 11:223.</a></li><li><a class="nounderline abstract_t">Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997; 157:1681.</a></li><li><a class="nounderline abstract_t">Robertson WO. Delayed hypoglycemia after ingestion of a single glipizide tablet. Ann Emerg Med 1999; 33:130.</a></li><li><a class="nounderline abstract_t">Levine M, Ruha AM, Lovecchio F, et al. Hypoglycemia after accidental pediatric sulfonylurea ingestions. Pediatr Emerg Care 2011; 27:846.</a></li><li><a class="nounderline abstract_t">Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989; 321:1231.</a></li><li><a class="nounderline abstract_t">Spiller HA, Sawyer TS. Toxicology of oral antidiabetic medications. Am J Health Syst Pharm 2006; 63:929.</a></li><li><a class="nounderline abstract_t">Eliasson L, Renström E, Ammälä C, et al. PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic beta cells. Science 1996; 271:813.</a></li><li><a class="nounderline abstract_t">Stahl M, Berger W. Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabet Med 1999; 16:586.</a></li><li><a class="nounderline abstract_t">Harrigan RA, Nathan MS, Beattie P. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. Ann Emerg Med 2001; 38:68.</a></li><li><a class="nounderline abstract_t">Tornio A, Niemi M, Neuvonen PJ, Backman JT. Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends Pharmacol Sci 2012; 33:312.</a></li><li><a class="nounderline abstract_t">Holstein A, Beil W, Kovacs P. CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. Expert Opin Drug Metab Toxicol 2012; 8:1549.</a></li><li><a class="nounderline abstract_t">Shobha JC, Muppidi MR. Interaction between voriconazole and glimepiride. J Postgrad Med 2010; 56:44.</a></li><li><a class="nounderline abstract_t">Boglou P, Steiropoulos P, Papanas N, Bouros D. Hypoglycaemia due to interaction of glimepiride with isoniazid in a patient with type 2 diabetes mellitus. BMJ Case Rep 2013; 2013.</a></li><li><a class="nounderline abstract_t">Schelleman H, Bilker WB, Brensinger CM, et al. Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide. Clin Pharmacol Ther 2010; 88:214.</a></li><li><a class="nounderline abstract_t">Spiller HA. Management of sulfonylurea ingestions. Pediatr Emerg Care 1999; 15:227.</a></li><li><a class="nounderline abstract_t">Holstein A, Hammer C, Hahn M, et al. Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. Expert Opin Drug Saf 2010; 9:675.</a></li><li><a class="nounderline abstract_t">Dizon AM, Kowalyk S, Hoogwerf BJ. Neuroglycopenic and other symptoms in patients with insulinomas. Am J Med 1999; 106:307.</a></li><li><a class="nounderline abstract_t">Hepburn DA, Deary IJ, Frier BM, et al. Symptoms of acute insulin-induced hypoglycemia in humans with and without IDDM. Factor-analysis approach. Diabetes Care 1991; 14:949.</a></li><li><a class="nounderline abstract_t">Towler DA, Havlin CE, Craft S, Cryer P. Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes 1993; 42:1791.</a></li><li><a class="nounderline abstract_t">Redmon B, Pyzdrowski KL, Elson MK, et al. Hypoglycemia due to a monoclonal insulin-binding antibody in multiple myeloma. N Engl J Med 1992; 326:994.</a></li><li class="breakAll">Bosse GM. Antidiabetic and hypoglycemic agents. In: Goldfrank's Toxicologic Emergencies, 9th ed, Goldfrank LR, Nelson LS, Lewin NA, et al (Eds), McGraw-Hill, New York 2011. p.714.</li><li><a class="nounderline abstract_t">Llamado R, Czaja A, Stence N, Davidson J. Continuous octreotide infusion for sulfonylurea-induced hypoglycemia in a toddler. J Emerg Med 2013; 45:e209.</a></li><li><a class="nounderline abstract_t">McLaughlin SA, Crandall CS, McKinney PE. Octreotide: an antidote for sulfonylurea-induced hypoglycemia. Ann Emerg Med 2000; 36:133.</a></li><li><a class="nounderline abstract_t">Braatvedt GD. Octreotide for the treatment of sulphonylurea induced hypoglycaemia in type 2 diabetes. N Z Med J 1997; 110:189.</a></li><li><a class="nounderline abstract_t">Carr R, Zed PJ. Octreotide for sulfonylurea-induced hypoglycemia following overdose. Ann Pharmacother 2002; 36:1727.</a></li><li><a class="nounderline abstract_t">Rath S, Bar-Zeev N, Anderson K, et al. Octreotide in children with hypoglycaemia due to sulfonylurea ingestion. J Paediatr Child Health 2008; 44:383.</a></li><li><a class="nounderline abstract_t">Glatstein M, Scolnik D, Bentur Y. Octreotide for the treatment of sulfonylurea poisoning. Clin Toxicol (Phila) 2012; 50:795.</a></li><li><a class="nounderline abstract_t">Fasano CJ, O'Malley G, Dominici P, et al. Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia. Ann Emerg Med 2008; 51:400.</a></li><li><a class="nounderline abstract_t">Dougherty PP, Lee SC, Lung D, Klein-Schwartz W. Evaluation of the use and safety of octreotide as antidotal therapy for sulfonylurea overdose in children. Pediatr Emerg Care 2013; 29:292.</a></li><li><a class="nounderline abstract_t">Hsu WH, Xiang HD, Rajan AS, et al. Somatostatin inhibits insulin secretion by a G-protein-mediated decrease in Ca2+ entry through voltage-dependent Ca2+ channels in the beta cell. J Biol Chem 1991; 266:837.</a></li><li><a class="nounderline abstract_t">Kutz K, Nüesch E, Rosenthaler J. Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol Suppl 1986; 119:65.</a></li><li><a class="nounderline abstract_t">Boyle PJ, Justice K, Krentz AJ, et al. Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses. J Clin Endocrinol Metab 1993; 76:752.</a></li><li><a class="nounderline abstract_t">Piters K. Chlorpropamide-induced hyponatremia. J Clin Endocrinol Metab 1976; 43:1085.</a></li><li><a class="nounderline abstract_t">Ludwig SM, McKenzie J, Faiman C. Chlorpropamide overdose in renal failure: management with charcoal hemoperfusion. Am J Kidney Dis 1987; 10:457.</a></li><li><a class="nounderline abstract_t">Moore DF, Wood DF, Volans GN. Features, prevention and management of acute overdose due to antidiabetic drugs. Drug Saf 1993; 9:218.</a></li><li><a class="nounderline abstract_t">Klein-Schwartz W, Stassinos GL, Isbister GK. Treatment of sulfonylurea and insulin overdose. Br J Clin Pharmacol 2016; 81:496.</a></li><li><a class="nounderline abstract_t">Szlatenyi CS, Capes KF, Wang RY. Delayed hypoglycemia in a child after ingestion of a single glipizide tablet. Ann Emerg Med 1998; 31:773.</a></li><li><a class="nounderline abstract_t">Palatnick W, Meatherall RC, Tenenbein M. Clinical spectrum of sulfonylurea overdose and experience with diazoxide therapy. Arch Intern Med 1991; 151:1859.</a></li><li><a class="nounderline abstract_t">Lung DD, Olson KR. Hypoglycemia in pediatric sulfonylurea poisoning: an 8-year poison center retrospective study. Pediatrics 2011; 127:e1558.</a></li><li><a class="nounderline abstract_t">Temple C, Hoang R, Kusin S. Home management of pediatric sulfonylurea ingestions. Clin Toxicol (Phila) 2022; 60:1235.</a></li></ol></div><div id="topicVersionRevision">Topic 308 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7848543" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Comparative tolerability profiles of oral antidiabetic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9250229" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9867907" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Delayed hypoglycemia after ingestion of a single glipizide tablet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21878825" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hypoglycemia after accidental pediatric sulfonylurea ingestions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2677730" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Oral hypoglycemic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16675650" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Toxicology of oral antidiabetic medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8628999" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic beta cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10445835" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11423816" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22475684" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23153186" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20393255" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Interaction between voriconazole and glimepiride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23595176" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hypoglycaemia due to interaction of glimepiride with isoniazid in a patient with type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20592722" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10389964" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Management of sulfonylurea ingestions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20553106" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10190379" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Neuroglycopenic and other symptoms in patients with insulinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1797507" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Symptoms of acute insulin-induced hypoglycemia in humans with and without IDDM. Factor-analysis approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8243825" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1545852" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hypoglycemia due to a monoclonal insulin-binding antibody in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1545852" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Hypoglycemia due to a monoclonal insulin-binding antibody in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23827165" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Continuous octreotide infusion for sulfonylurea-induced hypoglycemia in a toddler.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10918104" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Octreotide: an antidote for sulfonylurea-induced hypoglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9201206" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Octreotide for the treatment of sulphonylurea induced hypoglycaemia in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12398568" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Octreotide for sulfonylurea-induced hypoglycemia following overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18476935" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Octreotide in children with hypoglycaemia due to sulfonylurea ingestion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23046209" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Octreotide for the treatment of sulfonylurea poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17764782" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23426239" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Evaluation of the use and safety of octreotide as antidotal therapy for sulfonylurea overdose in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1702440" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Somatostatin inhibits insulin secretion by a G-protein-mediated decrease in Ca2+ entry through voltage-dependent Ca2+ channels in the beta cell.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2876508" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pharmacokinetics of SMS 201-995 in healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8445035" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/993312" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Chlorpropamide-induced hyponatremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3687936" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Chlorpropamide overdose in renal failure: management with charcoal hemoperfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8240727" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Features, prevention and management of acute overdose due to antidiabetic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26551662" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Treatment of sulfonylurea and insulin overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9624321" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Delayed hypoglycemia in a child after ingestion of a single glipizide tablet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1888253" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical spectrum of sulfonylurea overdose and experience with diazoxide therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21606145" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Hypoglycemia in pediatric sulfonylurea poisoning: an 8-year poison center retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36282178" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Home management of pediatric sulfonylurea ingestions.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
